StonvexLoading…
StonvexStonvexStonvexCore line items from CXT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $387.70M | $1.66B | $1.18B | $734.70M |
Operating Income | $22.20M | $246.70M | $167.10M | $85.20M |
Net Income | $6.40M | $145.10M | $97.10M | $46.60M |
EPS (Diluted) | $0.11 | $2.50 | $1.68 | $0.80 |
Total Assets | $3.64B | $3.12B | $2.92B | $2.92B |
Total Liabilities | $2.38B | $1.86B | $1.71B | $1.74B |
Cash & Equivalents | $228.30M | $233.80M | $182.40M | $152.50M |
Free Cash Flow OCF − CapEx | $-24.10M | $198.30M | $102.30M | $23.60M |
Shares Outstanding | 57.54M | 57.44M | 57.42M | 57.39M |